Jacob
Senior Member
- Reaction score
- 44
materials..
http://www.omegagenesis.com/resources/pdfs/OmegaGenesis Product Overview - Hair Growth.pdf
http://www.omegagenesis.com/resources/pdfs/BioCentury_Emerging_Company_Profile_May2009.pdf
http://www.thefreelibrary.com/Omega...technology+Platform+With+Broad...-a0190658055
http://www.omegagenesis.com/resources/pdfs/OmegaGenesis Product Overview - Hair Growth.pdf
OmegaGenesis is developing a nanotechnology solution to treat hairloss resulting from natural or medically induced causes. Based on the newly discovered angiogenic properties of inorganic nanorod materials, we are developing a topical product to treat hair loss. The product enhances blood supply to hair follicle, stimulates the hair roots and invigorates the growth cycle of hair.
A topical cream or gel will be applied to the scalp similar to other topical hair loss treatments. The nanorods are a size that allows penetration into the follicle cavity thereby allowing absorption in the dermal papilla. Data have shown both para- and intracellular transport of the nanorods indicating good percutaneous permeability characteristics.
Our product will dispensed by a dropper, from a collapsible laminated tube or metered dose pump as needed to ensure consistent application rates and dosing schedule.
A topical product is under development for use in hair loss. The product will be applied on a routine basis over several weeks to months to stimulate new hair growth through follicle restoration. The product may be used for an indefinite period to maintain hair growth for patients with androgenic alopecia, a progressive condition.
Once perifollicular vascularization has been stimulated, we anticipate a lower maintenance dose to reverse the effects of follicle shrinking. Further benefits may include accelerated hair regrowth and increased size of hair follicles and hair shafts.
The planned stages are:
• Pilot study completed and observed hair growth
• Material synthesis and formulation in progress for phase 2 pilot study – June, 2009
• Final Animal trials starts September 1, 2009
• Clinical trial proposed for February 1, 2010
http://www.omegagenesis.com/resources/pdfs/BioCentury_Emerging_Company_Profile_May2009.pdf
http://www.thefreelibrary.com/Omega...technology+Platform+With+Broad...-a0190658055
OmegaGenesis has developed novel methods to safely generate large-scale quantities of the nano-scale europium europium hydroxide rods, which were first developed at the Mayo Clinic and shown to promote angiogenesis , the formation of new blood vessels. The company has established non-toxicity of the europium hydroxide nanorods in lab testing for human applications and pre-clinical studies for use of the nanorods in the treatment of wound healing, diabetic foot ulcers and hair growth are underway
